Assessing the Effect of Patient Characteristics on Treatment Response in Primary Hyperhidrosis

Subject Recruitment

Recruitment will take place at SLUCare Dermatology Des Peres Clinic. Patients with non-study related appointments with Dr. Glaser regarding the management of primary hyperhidrosis will be approached by a research member. Patients will be given ample time to review study design and have questions and concerns addressed. After inclusion and exclusion criteria, study purpose and design, signed consent (parent or guardian will sign if subject is a minor), assent (for minors only, not signed) and HIPAA release are attained, the patients will be enrolled in the study.

The investigators will be recruiting two types of patients for this study. (1) New patients being seen for evaluation for primary hyperhidrosis. These subjects will be presenting to the hyperhidrosis clinic for the first time. If enrolled, these subjects will have all data prospectively collected. (2) Established patients being seen for ongoing management of primary hyperhidrosis who have documented baseline gravimetric measurements (defined as measurements taken while the patient was undergoing no active therapies for primary hyperhidrosis). These subjects will be presenting to the hyperhidrosis clinic for continued care. If enrolled, these subjects will have some data collected retrospectively with the remainder collected prospectively (see below for details).

Withdrawal or Discontinuation

Subjects may withdraw from the study at any time. If a subject desires withdraw from the study, the subject will be give a reason for study withdraw which will be included in publication. If a subject misses a scheduled visit the subject will be contacted via phone to ask if the subject is withdrawing from the study or reschedule a visit.

Because the subjects are only undergoing gravimetry, a non invasive way of measuring sweat production, it is highly unlikely that there would be any reason to discontinue a subjects participation due to safety. However, if at any point the supervising provider feels that a patient is at risk of harm the subject may be withdrawn from the study. In this case, a reason would be recorded for publication purposes.

Screen Failures

For those that fail screening, all information collected prior to that time will be shredded and disposed of in confidentiality trash bins. Only a reason for failing to pass screening will be recorded for publication purposes.

Subject Visits

Subjects will be screened, sign consent (parent or guardian will sign if subject is a minor), review assent (only applicable to minors) HIPAA release, and enrolled at an initial visit. Patients will have a monthly electronic or telephone survey to fill out. Patients will be seen every 3 months in clinic until the patient has achieved treatment response and/or no treatment changes are required. 6 months after this visit, the patient will be seen in clinic again***. If the subject has a sustained treatment response and/or has no treatment change, the subject will exit the study. If these conditions are not met, then the subject will resume 3 month visits.

It is important to note that these visit will overlap with non-study related visits that occur as a part of management of the patient's disease. Disease management decisions, such as which therapy to prescribe, will occur independently of this study and will not be affected by study participation. All visits will occur within 18 months after the study begins. No further study encounters will occur after this time period regardless of treatment changes or response.

*** Subjects may choose to forgo this 6 months visit and complete it electronically or by telephone.

New Patient

Subject Visit 1, 1 hour:

The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.

Through an interview with a research team member and chart review, the following data will be collected:

• Basic demographics
• Current treatments
• Hyperhidrosis Disease Severity Scale score (a scale that rates how the subject feels sweating affects daily activities) for all sites:
• Scalp
• Face
• Underarms
• Inframammary
• Chest
• Back
• Hands
• Feet
• Groin
• Buttocks
• Questionnaire regarding the subject's disease state (see attachment).

Patients will then undergo gravimetric measurements of all sites affected by hyperhidrosis as detailed in the attachment. Areas affected by HH will be defined by areas with an HDSS 3 or greater. For details on the gravimetry protocol, see attachment.

Subject Visits, follow-up, 30 minutes:

The following data will be collected through subject interview:

• Current treatment
• HDSS for all sites.
• Questionnaire regarding the subject's disease state (see attachment).
• Presence or absence of side effects

Patients will then undergo gravimetric measurements for sites with previous measurements. For detailed protocol see attachment.

Established Patient

Subject Visit 1, 1 hour:

The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.

Through chart review, the following data will be collected:

• Baseline (defined as data collected while the patient was not undergoing any treatment) HDSS score and gravimetric measurements for all sites
• Number of treatment changes since initiating care
• Basic demographics

Through an interview with the patient, the following information will be collected:

• Current treatment
• HDSS score for all sites
• Questionnaire regarding the subject's disease state (see attachment).
• Presence or absence side effects

Patients will then undergo gravimetric measurements for sites with previous gravimetric measurements.

Subject Visit, follow-up 30 minutes:

This will be the same as new patient follow up visits.

Subject Electronic/Telephone Survey: Monthly, 15 minutes

The following data will be collected through a phone or electronic interview between a research team member and the subject:

• Questionnaire regarding the subject's disease state (see attachment).